Forum Discussion
Perjeta access as second line treatment for HER2+ MBC - suggestions please
I was diagnosed with MBC in Nov 2011 (first diagnosis: mets to liver, bones, lung & brain), and have been feeling very well for years on Herceptin. However, this month, there has been new growth in t...
Hi Everyone,
It's been a year since I started self-funding Perjeta (I did 9 rounds of Taxol + Perjeta + Herceptin, now just on H+P). I feel great again, my scans are stable (no sign of the new growth from last year) and bloods are normal. However, I'm still self-funding under Roche's "Compassionate" Access program where they pay every third dose.
My frustration is I've paid for a year now to prove that Perjeta is working for me as a second line of treatment. My quality of life is excellent, but the financial strain is huge. Is there any progress in getting Perjeta approved as a subsequent line of treatment for MBC? My understanding is Roche haven't applied to TGA or PBAC for approval as a subsequent line of treatment? Has anyone heard of any trials for Perjeta as a second line of treatment? Is BCNA planning any further advocacy for patients in my situation?
Thanks for your advice,
Keely
It's been a year since I started self-funding Perjeta (I did 9 rounds of Taxol + Perjeta + Herceptin, now just on H+P). I feel great again, my scans are stable (no sign of the new growth from last year) and bloods are normal. However, I'm still self-funding under Roche's "Compassionate" Access program where they pay every third dose.
My frustration is I've paid for a year now to prove that Perjeta is working for me as a second line of treatment. My quality of life is excellent, but the financial strain is huge. Is there any progress in getting Perjeta approved as a subsequent line of treatment for MBC? My understanding is Roche haven't applied to TGA or PBAC for approval as a subsequent line of treatment? Has anyone heard of any trials for Perjeta as a second line of treatment? Is BCNA planning any further advocacy for patients in my situation?
Thanks for your advice,
Keely